An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

By Ludwig Burger and Michael Erman (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

Last month, Pfizer announced a $6 million agreement with 3SBio to develop, manufacture, and commercialize SSGJ-707, an additional bispecific antibody targeting PD-1 and VEGF pathways. According to ...

The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.